Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibodies - A Review
Ann Clin Trans Neurol 3:655-663, Venkatraman,A. & Opal,P., 2016
Bevacizumab in Glioblastoma - Still Much to Learn
NEJM 370:764-765, Fine, H.A., 2014
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Cavernous Maliformations of the Central Nervous System
NEJM 390:1022-1028, Smith,E.R., 2024
Spontaneous Subarachnoid Haemorrhage
Lancet 400:846-862, Claassen, J. & Park, S., 2022
Frequency and Predictors of Stroke After Acute Myocardial Infarction
Stroke 45:3514-3520, Hachet, O.,et al, 2014
Bone Marrow Necrosis and Fat Embolism Syndrome in Sickle Cell Disease: Increased Susceptibility of Patients with Non-SS genotypes and a Possible Association with Human Parvovirus B19 Infection
Blood Rev 28:23-30, Tsitsikas, D.A.,et al, 2014
Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
Recurrent Ischemic Events in Young Adults After First-Ever Ischemic Stroke
Ann Neurol 68:661-671, Putaala,J.,et al, 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Carotid Bruits as a Prognostic Indicator of Cardiovascular Death and Myocardial Infarction: A Meta-Analysis
Lancet 37:1587-1594,1555, Pickett,C.A.,et al, 2008
Elevated Troponin Levels are Associated with Higher Mortality Following Intracerebral Hemorrhage
Neurol 66:1330-1334, Hays,A. &Diringer,M.N., 2006
Prognostic Significance of Admission Levels of Troponin I in Patients With Acute Ischaemic Stroke
JNNP 76:76-81, Di Angelantonio,E.,et al, 2005
Update on Primary Central Nervous System Lymphoma
Curr Opin Neurol 18:645-653, Plotkin,S.R., 2005
Brain Metastases
The Neurologist 10:31-46, Klos,K.J.&O'Neill,B.P., 2004
Ischemic Stroke,Impact of a Recent Myocardial Infarction
Stroke 30:997-1001, Mooe,T.,et al, 1999
Prognosis of Patients with Symptomatic Vertebral or Basilar Artery Stenosis
WASID Study Group, Stroke 29:1389-13921998., , 1998
Anticardiolipin Antibodies & the Risk of Recurrent Thrombo-Occlusive Events & Death
The Antiphospholipid Antibodies & Stroke Study Group, Neurol 48:91-9497., , 1997
Predicting Complications of Carotid Endarterectomy
Stroke 24:1285-1291, McCrory,D.C.,et al, 1993
Frequency and Prognosis of Stroke/TIA Among 4808 Survivors of Acute Myocardial Infarction
Stroke 24:1490-1495, Tanne,D.,et al, 1993
Association Between Tumor Necrosis Factor-x and Disease Progression in Patients with Multiple Sclerosis
NEJM 325:467-472, Shareif,M.K.&Hentges,R., 1991
The Beneficial Effects of Early Dexamethasone Administration in Infants & Children with Bacterial Meningitis
NEJM 324:1525-1531, Odio,C.M.,et al, 1991
Central Nervous System Germinomas, A Review
Arch Neurol 48:652-657, Horowitz,M.B.&Hall,W.A., 1991